INAVOLISIB for Breast cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 36 adverse event reports in the FDA FAERS database where INAVOLISIB was used for Breast cancer.
Most Reported Side Effects for INAVOLISIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Hyperglycaemia | 54 | 28.7% | 2 | 19 |
| Blood glucose increased | 28 | 14.9% | 0 | 9 |
| Diarrhoea | 21 | 11.2% | 1 | 10 |
| Stomatitis | 20 | 10.6% | 1 | 3 |
| Fatigue | 18 | 9.6% | 0 | 3 |
| Thrombocytopenia | 16 | 8.5% | 0 | 1 |
| Off label use | 14 | 7.5% | 2 | 6 |
| Diabetic ketoacidosis | 13 | 6.9% | 2 | 7 |
| Nausea | 13 | 6.9% | 0 | 3 |
| Neutropenia | 10 | 5.3% | 0 | 0 |
| Anaemia | 7 | 3.7% | 0 | 1 |
| White blood cell count decreased | 7 | 3.7% | 0 | 1 |
| Acute kidney injury | 6 | 3.2% | 0 | 5 |
| Asthenia | 6 | 3.2% | 0 | 1 |
| Death | 6 | 3.2% | 4 | 1 |
Other Indications for INAVOLISIB
Breast cancer metastatic (70)
Product used for unknown indication (30)
Breast cancer female (6)
Hormone receptor positive breast cancer (6)
Other Drugs Used for Breast cancer
TRASTUZUMAB (15,522)
PALBOCICLIB (13,075)
DOCETAXEL (11,735)
PACLITAXEL (10,215)
LETROZOLE (9,332)
CYCLOPHOSPHAMIDE (8,826)
PERTUZUMAB (7,532)
RIBOCICLIB (6,953)
CAPECITABINE (5,767)
EPIRUBICIN (5,444)